ResMed Inc. (NYSE:RMD) Shares Bought by MML Investors Services LLC

MML Investors Services LLC raised its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 31.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,468 shares of the medical equipment provider's stock after purchasing an additional 2,771 shares during the quarter. MML Investors Services LLC's holdings in ResMed were worth $2,623,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RMD. Vanguard Group Inc. boosted its position in shares of ResMed by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider's stock worth $4,156,089,000 after purchasing an additional 160,590 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of ResMed by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider's stock valued at $899,860,000 after purchasing an additional 85,270 shares during the period. Invesco Ltd. grew its position in ResMed by 32.2% during the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider's stock worth $531,706,000 after buying an additional 566,046 shares during the period. Charles Schwab Investment Management Inc. grew its position in ResMed by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 957,020 shares of the medical equipment provider's stock worth $218,861,000 after buying an additional 32,973 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in ResMed by 9.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 742,412 shares of the medical equipment provider's stock valued at $169,789,000 after buying an additional 65,999 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Insider Buying and Selling

In related news, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the sale, the director now directly owns 77,218 shares in the company, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $209.85, for a total value of $1,680,688.65. Following the transaction, the chief executive officer now directly owns 455,472 shares in the company, valued at $95,580,799.20. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 49,013 shares of company stock valued at $11,298,816. 0.71% of the stock is currently owned by company insiders.

ResMed Trading Down 0.1 %

ResMed stock traded down $0.17 during trading on Thursday, hitting $236.42. The company's stock had a trading volume of 464,092 shares, compared to its average volume of 1,008,764. The stock's fifty day moving average is $222.10 and its 200 day moving average is $234.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. ResMed Inc. has a 1-year low of $179.42 and a 1-year high of $263.05. The stock has a market capitalization of $34.72 billion, a price-to-earnings ratio of 27.98, a P/E/G ratio of 1.53 and a beta of 0.75.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the prior year, the firm posted $2.13 EPS. The company's revenue was up 7.9% on a year-over-year basis. As a group, equities research analysts predict that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, May 8th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. ResMed's payout ratio is 23.79%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on RMD shares. JPMorgan Chase & Co. upped their price target on ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Morgan Stanley initiated coverage on ResMed in a research note on Wednesday, March 19th. They set an "overweight" rating and a $280.00 price target for the company. Royal Bank of Canada boosted their price objective on shares of ResMed from $247.00 to $255.00 and gave the stock a "sector perform" rating in a research report on Thursday, April 24th. Stifel Nicolaus dropped their target price on shares of ResMed from $250.00 to $240.00 and set a "hold" rating for the company in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group started coverage on shares of ResMed in a report on Thursday, January 16th. They issued a "buy" rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $258.83.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.